You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Allergen immunotherapy has been shown to be efficacious in numerousstudies for the clinical indications of allergic asthma andrhinitis, as well as hymenoptera venom hypersensitivity. Howallergen immunotherapy improves clinical symptoms is still notentirely clear. Decreases in specific IgE follow a complex cascadeof effects: a shifting of the cytokine milieu from TH2 to TH1predominance, with resultant decrease in interleukin 4, decreasedrecruitment and activation of eosinophils, and decreased proliferationof mast cells. Allergen exposure has a lessened ability to stimulatean inflammatory cell response, with decreased target organ hyperreactivity.Since allergen immunotherapy is not without risk, the decisionneeds to be made whether injection therapy is safe and providesbenefit not achievable by medical management. The continuedclarification of optimal allergen concentrations through carefulstudies of standardized extracts will allow better control ofadverse events by limiting unnecessarily potent mixtures.